ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.
暂无分享,去创建一个
B. Coiffier | N. Mounier | P. Lugtenburg | B. Glimelius | I. Aurer | F. Morschhauser | P. Brice | C. Fortpied | P. Carde | D. Caillot | M. Seftel | A. Sureda | H. Khaled | M. Wolf | M. Karrasch | S. Bologna | G. Cantin | I. Gaillard | C. Fermé